-
公开(公告)号:US07294622B2
公开(公告)日:2007-11-13
申请号:US10528640
申请日:2003-10-02
申请人: Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Bhikkappa Shenvi , Thomas Simpson , James Woods
发明人: Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Bhikkappa Shenvi , Thomas Simpson , James Woods
IPC分类号: C07D223/16 , C07D267/14 , C07D281/06 , A61K31/55 , A61P25/28
CPC分类号: C07K5/06034 , A61K38/00 , C07D223/16 , C07D267/10 , C07D267/14 , C07D281/06 , C07D281/10 , C07D405/04 , C07D417/12 , C07D417/14 , C07K5/06026 , C07K5/06191
摘要: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid β protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
摘要翻译: 具有式(I)的药物组合物和含有它们的药物组合物及其用于治疗与淀粉样蛋白β蛋白生产和神经障碍如阿尔茨海默病有关的神经障碍的方法。 这些化合物抑制γ分泌酶,从而抑制淀粉样蛋白β蛋白的产生,从而起到防止淀粉样蛋白的神经沉积的形成的作用。
-
公开(公告)号:US20060089346A1
公开(公告)日:2006-04-27
申请号:US10528640
申请日:2003-10-02
申请人: Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
发明人: Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
IPC分类号: A61K31/554 , A61K31/55 , A61K31/551
CPC分类号: C07K5/06034 , A61K38/00 , C07D223/16 , C07D267/10 , C07D267/14 , C07D281/06 , C07D281/10 , C07D405/04 , C07D417/12 , C07D417/14 , C07K5/06026 , C07K5/06191
摘要: Compounds having the formula (1) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid B protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
摘要翻译: 具有式(1)的药物组合物及其用于治疗与淀粉样蛋白B蛋白质产生和神经障碍如阿尔茨海默病相关的神经障碍的方法。 这些化合物抑制γ分泌酶,从而抑制淀粉样蛋白β蛋白的产生,从而起到防止淀粉样蛋白的神经沉积的形成的作用。
-
公开(公告)号:US20080076752A1
公开(公告)日:2008-03-27
申请号:US11844451
申请日:2007-08-24
申请人: Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
发明人: Christopher Becker , Bruce Dembofsky , Robert Jacobs , James Kang , Cyrus Ohnmacht , James Rosamond , Ashokkumar Shenvi , Thomas Simpson , James Woods
IPC分类号: A61K31/554 , A61P25/28
CPC分类号: C07K5/06034 , A61K38/00 , C07D223/16 , C07D267/10 , C07D267/14 , C07D281/06 , C07D281/10 , C07D405/04 , C07D417/12 , C07D417/14 , C07K5/06026 , C07K5/06191
摘要: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid β protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
摘要翻译: 具有式(I)的药物组合物和含有它们的药物组合物及其用于治疗与淀粉样蛋白β蛋白生产和神经障碍如阿尔茨海默病有关的神经障碍的方法。 这些化合物抑制γ分泌酶,从而抑制淀粉样蛋白β蛋白的产生,从而起到防止淀粉样蛋白的神经沉积的形成的作用。
-
公开(公告)号:US20070179172A1
公开(公告)日:2007-08-02
申请号:US10553915
申请日:2004-05-04
申请人: Christopher Becker , Jeanne Comstock , William Michne , Megan Murphy , Eifion Phillips , James Rosamond , Thomas Simpson
发明人: Christopher Becker , Jeanne Comstock , William Michne , Megan Murphy , Eifion Phillips , James Rosamond , Thomas Simpson
IPC分类号: A61K31/4743 , A61K31/4741 , A61K31/473
CPC分类号: A61K31/4709 , A61K31/47
摘要: Compounds of Formula I or Formula II wherein R1, X and Ar are as described in the specification, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.
摘要翻译: 其中R 1,X和Ar如说明书中所述的式I或式II化合物,其药学上可接受的盐,制备方法,含有它们的药物组合物及其在治疗中的用途,特别是 用于治疗与烟碱传播减少有关的病症。
-
公开(公告)号:US20050245595A1
公开(公告)日:2005-11-03
申请号:US11178668
申请日:2005-07-11
申请人: David Gurley , James Rosamond
发明人: David Gurley , James Rosamond
IPC分类号: C07D413/04 , A61K31/404 , A61K31/422 , A61K45/00 , A61K45/06 , A61P1/04 , A61P25/00 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/28 , A61P25/34 , A61P43/00 , C07D209/04 , C07D209/12 , C07D209/42 , A61K31/405
CPC分类号: C07D209/04 , A61K45/06 , C07D209/12 , C07D209/42 , C07D413/04
摘要: Compounds according to formula I: wherein R1, W, R2, R3, X, R4 and R5 are as described in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.
摘要翻译: 根据式I的化合物:其中R 1,W,R 2,R 3,X,R 4, 和R 5如说明书中所述,其对映体,其药学上可接受的盐,其制备方法,含有它们的药物组合物及其在治疗中的用途,特别是用于治疗与烟碱减少有关的病症 传输。
-
公开(公告)号:US06750242B1
公开(公告)日:2004-06-15
申请号:US10111027
申请日:2002-09-23
申请人: David Gurley , Thomas Lanthorn , John Macor , James Rosamond
发明人: David Gurley , Thomas Lanthorn , John Macor , James Rosamond
IPC分类号: A61K31404
CPC分类号: C07D407/12 , A61K45/06 , C07D209/08 , C07D209/18
摘要: Compounds of Formula I wherein R1, R2, R3 and R4 are as defined in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. The compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
摘要翻译: R 1,R 2,R 3和R 4中的式I化合物如本说明书中所定义,其对映体,其药学上可接受的盐,制备方法,含有它们的药物组合物及其用途 在治疗中,特别是用于治疗与烟碱传播减少有关的病症。 本发明的化合物增强了激动剂在烟碱受体上的功效。
-
公开(公告)号:US07402604B2
公开(公告)日:2008-07-22
申请号:US11178668
申请日:2005-07-11
申请人: David Gurley , James Rosamond
发明人: David Gurley , James Rosamond
IPC分类号: A61K31/405 , C07D209/42
CPC分类号: C07D209/04 , A61K45/06 , C07D209/12 , C07D209/42 , C07D413/04
摘要: Compounds according to formula I: wherein R1, W, R2, R3, X, R4 and R5 are as described in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.
摘要翻译: 根据式I的化合物:其中R 1,W,R 2,R 3,X,R 4, 和R 5如说明书中所述,其对映体,其药学上可接受的盐,其制备方法,含有它们的药物组合物及其在治疗中的用途,特别是用于治疗与烟碱减少有关的病症 传输。
-
公开(公告)号:US07064143B1
公开(公告)日:2006-06-20
申请号:US10111029
申请日:2000-11-01
申请人: David Gurley , James Rosamond
发明人: David Gurley , James Rosamond
IPC分类号: A61K31/404 , C07D209/04
CPC分类号: C07D209/04 , A61K45/06 , C07D209/12 , C07D209/42 , C07D413/04
摘要: Compounds of Formula I wherein R1, R2, R3, R4, R5, W and X as defined in the specification, enantiomers thereof, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. Compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
摘要翻译: 式I的化合物,其中R 1,R 2,R 3,R 4,R 5, 本说明书中定义的对映异构体,其药学上可接受的盐,其制备方法,含有它们的药物组合物及其在治疗中的用途,特别是用于治疗与烟碱转移相关的病症相关的病症。 本发明的化合物增强了激动剂在烟碱受体上的功效。
-
公开(公告)号:US06756398B1
公开(公告)日:2004-06-29
申请号:US10111028
申请日:2002-04-18
申请人: Michael Balestra , David Gurley , James Rosamond
发明人: Michael Balestra , David Gurley , James Rosamond
IPC分类号: C07D20908
CPC分类号: C07D209/08 , A61K31/404 , A61K45/06
摘要: Compounds of Formula I wherein R1a, R1b, R2b, R3b, R3a, R2a, B1, B2, Z, A2 and A1 are as defined in the specification, enantiomers thereof, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. Compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
摘要翻译: R 1,R 1b,R 2b,R 3b,R 3a,R 2a,B 1,B 2,Z,A 2中的式I化合物, 和A 1如本说明书中所定义,其对映异构体,其药学上可接受的盐,制备方法,含有它们的药物组合物及其在治疗中的用途,特别是用于治疗与烟碱传递减少有关的病症。 本发明的化合物增强了激动剂在烟碱受体上的功效。
-
-
-
-
-
-
-
-